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ABSTRACT 
Background and Objective:  ‘Natural selection’ has been shown to have enriched the genomes of high-
altitude native populations with genetic variants of advantage in this hostile hypoxic environment. In 
lowlanders who ascend to altitude, genetic factors may also contribute to the substantial interindividual 
variation in exercise performance noted at altitude. We performed a systematic literature review to 
identify genetic variants of possible influence on human hypoxic exercise performance, commenting on 
the strength of any identified associations. 
Criteria for considering studies for this review:  All studies of the association of genetic factors with 
human hypoxic exercise performance, whether at sea level using ‘nitrogen dilution of oxygen’ 
[normobaric hypoxia], or at altitude or in low-pressure chambers [field or chamber hypobaric hypoxia 
respectively] were sought for review.   
Search strategy for identification of studies:  Two electronic databases were searched (Ovid MEDLINE, 
Embase) up to January 31st 2014. We also searched the reference lists of relevant articles for eligible 
studies. All studies published in English were included as were studies in any language for which the 
abstract was available in English.   
Data collection and analysis:  Studies were selected and data extracted independently by two 
reviewers.  Differences regarding study inclusion were resolved through discussion. The quality of each 
study was assessed using a scoring system based on published guidelines for conducting and reporting 
genetic association studies.  
Results:  Eleven studies met all inclusion criteria and were included in the review. Subject numbers 
ranged from 20 to 1,931 and consisted of healthy individuals in all cases. The maximum altitude of 
exposure ranged from 2,690 to 8848 m. The exercise performance phenotypes assessed were 
mountaineering performance (n = 4), running performance (n = 2), and maximum oxygen consumption 
(V̇O2max) (n = 4). In total, thirteen genetic polymorphisms were studied, four of which were associated 
with hypoxic exercise performance. The  adenosine monophosphate deaminase (AMPD1) C34T 
(rs17602729), beta2-adrenergic receptor (ADRB2) Gly16Arg SNP (rs1042713), and androgen receptor 
CAG repeat polymorphisms were associated with altitude performance in one study, and the 
angiotensin I-converting enzyme (ACE) insertion/deletion (I/D) (rs4646994) polymorphism was 
associated with performance in three studies. The median score achieved in the study quality analysis 
was 6 out of 10 for case control studies, 8 out of 10 for cohort studies with a discrete outcome, 6 out of 
9 for cohort studies with a continuous outcome, and 4.5 out of 8 for genetic admixture studies. 
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Conclusion: The small number of articles identified in the current review and the limited number of 
polymorphisms studied in total highlights that the influence of genetic factors on exercise performance 
in hypoxia has not been studied in depth, which precludes firm conclusion being drawn. Support for the 
association between the ACE I allele and improved high altitude performance was the strongest, with 
three studies identifying a relationship. Analysis of study quality highlights the need for future studies in 
this field to improve the conduct and reporting of genetic association studies. 
Key Points 
1. The size and scope of the literature regarding the role of genetics on high altitude exercise 
performance is limited 
2. The association between the angiotensin I-converting enzyme (ACE) insertion (I) allele and improved 
high altitude performance has the strongest support 
3. The volume and quality of the literature limits firm conclusion being made and needs to be addressed 
in future studies 
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1 Introduction 
With ascent to altitude, barometric pressure falls, and with it the partial pressure of inspired oxygen 
(PiO2). Despite diverse adaptive responses, the arterial partial pressure of oxygen (PaO2) also falls. Such 
‘hypobaric hypoxia’ impairs physical performance and can cause pathology (acute mountain sickness, 
AMS) which may be fatal (e.g. high altitude pulmonary oedema (HAPE) or high altitude cerebral oedema 
(HACE)). 
 
Longstanding communities of high-altitude residents exist worldwide, most notably on the Tibetan 
Plateau and Andean Altiplano, but also in the area of the Great Rift Valley in Ethiopia. ‘Natural selection’ 
has enriched the genomes of high-altitude native populations conferring advantage in this hostile 
hypoxic environment [1]. Meanwhile, increasing numbers of native lowlanders travel to high altitude for 
recreation or work. Amongst these lowland populations, similar genetic factors may contribute to the 
substantial inter-individual variation in exercise performance and wellbeing observed at altitude [2, 3]. 
Whilst attempts have been made to identify genetic variants associated with improved high-altitude 
performance, the results of such studies have yet to be collated. We thus set out to systematically 
review the published literature and identify genetic variants of influence on human hypoxic exercise 
performance, commenting on the strength of any identified associations.  
 
2 Methods 
2.1 Search strategy  
2.1.1 Criteria for considering studies for this review 
All studies of the association of genetic factors with human hypoxic exercise performance, whether at sea 
level using ‘nitrogen dilution of oxygen’ [normobaric hypoxia], or at altitude or in low-pressure chambers 
[field or chamber hypobaric hypoxia, respectively] were sought for review.  ‘Altitude’ was defined as a real or 
simulated (normobaric hypoxia) elevation of >2000m above sea level.  Performance measures were defined as 
any measure of aerobic exercise capacity (such as V̇O2max or V̇O2peak) or of exercise performance (e.g. a 
timed physical challenge).  Studies were included if they evaluated exercise performance under conditions of 
hypoxia or changes in sea-level performance following hypoxic exposure.  Case-control studies were included 
where cases were successful performers at >2000m, and where appropriate control groups (by race and by 
similar altitude of origin [±500m]) were utilised.  Only human studies and full primary research papers (e.g. 
not conference abstract, letter to the editor, or review) were eligible for inclusion.  Studies of high-altitude 
population genetics per se were excluded unless specifically assessing a physical performance phenotype.  
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Research articles were excluded if they did not seek to identify genetic factors and their relationship with 
hypoxic exercise performance.  
 
2.1.2 Search strategy for identification of studies 
The following electronic databases were searched: Ovid MEDLINE(R) Daily Update <January 31, 2014>, Ovid 
OLDMEDLINE(R) <1946 to 1965>, Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations, Ovid 
MEDLINE(R) <1946 to Present> and Embase Classic+Embase <1947 to 2014 January 31>.  Ovid MEDLINE is 
produced by the National Library of Medicine and indexes information from approximately 5,600 journals in 
the fields of biomedicine and related fields. Embase is an Elsevier database that indexes biomedical and 
pharmacological bibliographic records from articles published in more than 7, 500 peer reviewed journals. All 
studies published in English were included in the search as were studies in any language for which the abstract 
was available in English.  No other limits were applied. 
 
We developed a search strategy based on the ‘patient or population, intervention, comparison, outcome’ 
(PICO) framework. However, the types of study we sought do not conform exactly to the PICO format, which 
could not therefore be fully adhered to: in particular, all populations were eligible for inclusion, making the 
‘patient or population’ parameter redundant.  In order to formulate a research question, each search 
contained one term from each of the following three parameters (intervention, comparison, and outcome) 
with each term linked by the Boolean operator ‘AND’. The full search strategy run in the various databases can 
be found in Electronic Supplementary Material Appendix S1 and Appendix S2.  In brief, the key terms used in 
the search are listed hereafter, and these were also used to identify synonyms and related terms (which were 
also searched for):  
 Intervention: Altitude, anoxia, or hypoxia;  
 Comparison: Gene frequency, genotype, polymorphism, haplotype, single nucleotide polymorphism, 
or genetic linkage;  
 Outcome: Exercise tolerance, exercise test, exercise, athletic performance, performance, 
mountaineering, summit, physical endurance, endurance. 
 
2.1.3 Searching other resources 
In addition to electronic databases, we searched bibliographies of included articles for research papers. 
Research papers with titles that indicated that the study was in the scope of the current review were retrieved 
and underwent the formal review process.   
6 
 
 
2.1.4 Data collection and analysis 
In the first stage of the review process, two authors (PJH, AFO) independently inspected all citations 
from the searches (using information contained in the title, keywords and abstract) to identify candidate 
articles for which full texts were retrieved.  If any ambiguity arose regarding the inclusion or exclusion of 
an article due to the absence of key information, the full text article was obtained.  In the second stage, 
the authors (PJH, AFO) independently applied the inclusion and exclusion criteria to the candidate full 
text articles.  At both stages of the process, differences regarding study inclusion were resolved through 
discussion.  
 
2.1.5 Data extraction and management 
From each source document, the lead author (PJH) extracted data including study identification 
information, number of participants in each group, demographic information (including the sex, age and 
ethnicity, race or origin of the participants), magnitude of hypoxic exposure (altitude or hypoxic 
exposure), polymorphism and/or gene or region being studied, gene and allele frequencies, probability 
values from comparisons, measure of performance, and the information required to assess the quality 
of each study (see table 1).  Studies were separated according to their primary study design (case-
control or cohort).  Odds ratios were determined for studies with categorical outcomes variables using 
an additive model.  
 
2.2 Study quality analysis 
The quality of each study was assessed using a scoring system (Table 1) adapted from Clark and 
Baudouin [4], which was based on published guidelines for conducting and reporting genetic association 
studies. Different aspects of the study were scored 1 if the information was present or 0 if it was not. 
These were then summed to give a final score which ranged from 0-10 for case-control studies, 0-9 for 
cohort studies, and 0-8 for genetic admixture studies.  We modified the approach of Clark and Baudouin 
[4] in relation to sample size and power calculations. Studies were deemed adequate in this respect if a 
power calculation was reported, but we did not perform a power calculation for studies where this was 
not reported. The criteria used for considering the quality of the control group were also adapted. In the 
original system by Clark and Baudouin [4] a study that used a control group from a previously published 
study would need to describe the population in sufficient detail to meet the study quality criteria to 
score. Due to word restrictions imposed by publishers and the need to avoid repetition, we extended 
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this.  In studies that provided a reference to a control population the referenced study was retrieved 
and the control group analysed according to the original criteria. We also altered the methods used to 
assess the reproducibility of genotyping to allocate a score both to studies that provided their own 
validation results, and to those that provided a reference to a study using the same procedures which 
included validation information.  
 
3 Results 
3.1 Results of the search 
The initial search identified 307 articles (see figure 1). After removing duplicate articles, 213 remained 
for the first evaluation. Following review of the title, abstract and key words of these records, 12 
candidate articles were identified that met the predefined criteria, and full text versions were obtained 
for further review. Four candidate articles did not meet the review inclusion criteria and were therefore 
rejected, leaving eight eligible articles for appraisal [5-12]. Examination of the full text version of these 
articles and their bibliographies identified three additional eligible articles [13-15].  Eleven articles were 
included in the final analysis. 
 
3.2 Description of included studies 
The eleven studies reviewed can be separated into those comparing the frequency of genotypes or 
alleles between two groups (case-control) (Table 2) [6, 15]; cohort studies where participants were 
separated according to task success or failure and where genotype or allele frequencies were compared 
between groups (Table 3) [8-10]; and cohort studies comparing the difference in performance measures 
(continuous variable) between individuals grouped by genotype or allele (Table 4) [6, 7, 11, 12]. Two 
studies used a different approach, and examined whether Spanishcompared to Quechua genetic 
admixture explained differences in V̇O2max at high altitude [13, 14]. According to the location of the 
corresponding author, studies were from the United Kingdom (n=4), the USA (n=3), Greece (n=1), New 
Zealand (n=1), South Africa (n=1), and China (n=1). The number of subjects in each study varied from 20 
to 1,931, and consisted of healthy males in four studies [12-15] and healthy males and females in 6 
studies [5, 7-11], with sex of the participants not stated in one study [6]. The maximum altitude of 
exposure ranged from 2690 to 8848m. The exercise performance phenotype assessed was 
mountaineering performance in five studies [6, 8-10, 15], running performance in two studies [7, 11] 
and maximum oxygen consumption in four studies [5, 12-14]. In total, 13 genetic polymorphisms located 
within 10 different genes were studied, excluding those used to estimate genetic admixture by Brutsaert 
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and colleagues [13, 14]. The most studied gene was that encoding the angiotensin I-Converting Enzyme 
(ACE) which was studied in seven separate papers. The names of all the genes studied, excluding those 
used to indicate Quechua and Spanish ancestry by Brusaert and co-workers [13, 14], are listed in Table 5 
along with the symbols and the chromosomal location. Results are presented according to the genetic 
polymorphism of interest, then by phenotype of interest (given sub-heading where necessary), and are 
ordered based on the maximum altitude studied.  
 
3.3 ACE insertion/deletion (I/D) polymorphism (rs4646994) 
Seven studies investigated the association of the ACE I/D (rs4646994) polymorphism with exercise 
performance at altitude. Two were case-controlled studies which compared genotype or allele 
frequencies between high-altitude mountaineers and a control population (Table 2). Five cohort studies 
were also conducted; in three of these, study participants were separated according to task success or 
failure and genotype and/or allele frequencies were compared between groups (Table 3), whilst four 
studies compared performance phenotype (as a continuous variable [e.g. time and V̇O2max]) between 
those of different genotype (Table 4).  
 
3.3.1 Mountaineering performance 
In a prospective study, Tsianos et al. [10] reported the ACE I-allele to be associated with successful 
ascent of Mont Blanc (4807m).  ACE genotype distribution varied between Caucasian climbers who 
successfully summited Mt Blanc (n=183) and those who tried and failed (n=12) (P=0.048) (odds ratio, 
3.41), the I allele being more prevalent in those that summited compared to those that did not (0.47 vs 
0.21, P=0.01) (Table 3).  The proportion of those of each genotype who successfully summited was 
87.7%, 94.9% and 100% for the DD, ID, and II genotypes, respectively.  
 
Kalson et al. [8] prospectively studied Caucasian trekkers attempting to climb Mt Kilimanjaro (5895m), 
participants being separated by ascent rate (4 days [‘direct’] vs 5 days [‘slow’]). Genotype distribution 
did not differ by success rate in the ‘slow’ group II 9 (0.22), ID 18 (0.44), DD 14 (0.34) successful versus II 
9 (0.22), ID 22 (0.54), DD 10 (0.24) unsuccessful, P = 0.54; I allele frequency 0.44 versus 0.49 
respectively; odds ratio, 0.82). In ‘fast ascent’ subjects, ACE genotype distribution was II 6 (0.30) vs ID 11 
(0.55) vs DD 3 (0.15) in those successful and II 0 (0.00) vs ID 10 (0.71) vs DD 4 (0.29) in those who failed 
(P = 0.09). I-allele frequency for those successful versus those who failed was 0.58 versus 0.36 (odds 
ratio, 2.44) (Table 3). 
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Montgomery et al. [15] studied ACE genotype in 25 elite British high-altitude mountaineers who had 
frequently ascended beyond 7000m without supplementary oxygen. When compared to 1906 British 
controls (free from clinical cardiovascular disease), the I allele was found to be over-represented in cases 
(P = 0.003), as was ACE II genotype (proportion 0.48 vs 0.23 in cases vs controls respectively) (odds ratio, 
2.43) (Table 2). The DD genotype was not present in any individual who had previously ascended beyond 
8000m.  
 
Djarova et al. [6] also reported I allele prevalence to be greater in 5 elite Bulgarian mountaineers (all 
climbed above 7500m without supplementary oxygen) than in 72 Bulgarian student controls (0.60 vs 
0.41 respectively, P = 0.002) (odds ratio, 2.29). ACE genotype distribution differed, largely due to an 
excess of ID genotype in the elite group (P=0.024) (Table 2). The small case population (n=5) limits 
confidence in this finding. Further, we were unable to replicate their statistical analysis: using the ACE 
allele frequencies and population numbers stated in the paper, and applying Fisher’s exact test (as the 
authors did) in a commonly used statistical package (SPSS 21, SPSS Inc., Chicago, IL, USA), we were 
unable to demonstrate a statistically significant difference in ACE allele frequencies between the two 
groups (P = 0.203). The same held true for the two other polymorphisms they studied, which were the 
alpha actinin-3 ACTN3 R577X (rs1815739) and the adenosine monophosphate deaminase (AMPD1) C34T 
polymorphisms (rs17602729). 
 
Thompson et al. (2007) extended the observations of Tsianos et al. [10], Karlson et al. [8] and 
Montgomery et al. [15] to individuals attempting to climb beyond 8000m, the maximum altitude 
attained by each individual and the reason for failure also being noted. Once again, in a population of 
Caucasian and Asian mountaineers, ACE genotype distribution differed between successful summiteers 
(n=92) and those who failed (n=57) (odds ratio, 2.15) (Table 3) (P=0.003), both II genotype and the I 
allele being more prevalent in the successful group (II genotype 0.33 vs 0.06 (P=0.003); I allele, 0.55 vs 
0.36 for success vs failure respectively). Maximum altitude attained (as a continuous variable) was also 
related to ACE I allele, being 8079m, 8107m, and 8559 m for those of DD, ID and II genotype respectively 
(allele comparison, P=0.0023).  
 
3.3.2 Maximum oxygen uptake (V̇O2max) at altitude 
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Bigham et al. [5] reported the relationship of ACE genotype with V̇O2max at 4338m in Peruvian high-
altitude native residents (n=74) and in Peruvian low-altitude residents whose family originate from high 
altitude (n=68). V̇O2max did not differ by genotype, even when other cofactors, such as altitude of 
residence, were accounted for (Table 4).   
 
3.3.3 Sea level running performance 
Hinckson et al. [7] studied whether improvement in sea level exercise performance following hypoxic 
exposure (2500-3500m) was related to ACE genotype (Table 4). This study was primarily designed to test 
the efficacy of hypoxic training for improving running performance. It included a study group whose 10 
participants were exposed to four weeks of hypoxia for > 10 hrs per day, and ten controls who had no 
hypoxic exposure. In eight participants (ethnicity not disclosed) in the study group, the relationship 
between improvements in running performance following hypoxic training with ACE I/D genotype was 
sought (Table 3). Neither numerical results by genotype nor statistical analysis, however, are reported – 
although a figure suggests a lack of genotype association.  
 
3.4 ACTN3 R577X (rs1815739) 
Two studies tested if an association was present between the ACTN3 R577X polymorphism and high 
altitude exercise performance. Tsianos et al. [11] included the ACTN3 RX polymorphism as one of eleven 
polymorphisms (in eight genes) for which an association was sought with performance in the Mt 
Olympus Marathon (maximum altitude of 2690m). In all, no such association was identified in 438 
participants over two years of racing. The distribution of the ACTN genotypes in the small elite high 
altitude mountaineer cohort (n=5) tested by Djarova et al. [6] was RR 1 (0.20), RX 3 (0.60), and XX 1 
(0.20) compared to RR 30 (0.42), RX 32 (0.44) and XX 10 (0.14) in the control group (n=72). The allele 
frequencies between the two groups were different (p = 0.032) with a relative excess of the X allele in 
the mountaineers (odds ratio, 1.77) (Table 2).  However, as discussed in the previous section, the 
statistical approach of Djarova et al. [6] was of questionable validity. Using the allele frequencies and 
subject numbers from the paper [6], we found no difference in the ACTN RX allele distributions between 
the two populations (P = 0.501).  
 
3.5 AMPD1 C34T (rs17602729) 
In the study by Tsianos et al. [11] (see previous section) the adenosine monophosphate deaminase 
(AMPD) C34T polymorphism was not associated with Mt Olympus Marathon performance for the whole 
11 
 
group studied, but sub-group analysis revealed a modest association between the T allele (referred to as 
the ‘A allele’ in Tsianos et al. [11]) and better performance in athletes whose preferred sport was 
running (event completion time, P = 0.021; best ever time, p = 0.03). Djarova et al. [6] found that the 
frequency of the T allele was higher in mountaineers than in controls (p = 0.032; odds ratio, 2.82) (Table 
2). However, as stated in the previous two results sections, the statistical analysis in this study is 
incorrect; by using the reported allele frequencies in a Fishers test we found no difference in the 
distribution of the allele of the AMPD1 C34T polymorphism between the elite mountaineers and 
controls (P=0.155).  
 
3.6 Other polymorphisms 
Ten other polymorphisms were studied. Of nine studied by Tsianos et al. [11] (listed in Table 4) the 
beta2-adrenergic receptor (ADRB2) Gly16Arg SNP (rs1042713) was associated with performance in the 
Mt Olympus Marathon. In the study by Tsianos et al. [11], the Arg allele was associated with a shorter 
time to complete the race amongst people who chose running as their preferred exercise mode (P = 
0.015), and with best ever Mt Olympus Marathon time for those who have completed the event 
multiple times (P=0.003).  Meanwhile, Wang et al. [12] studied the association between the androgen 
receptor (AR) CAG repeat polymorphism and V̇O2max changes in 65 unrelated Han Chinese college 
athletes following a 30 day bout of intermittent hypoxic exposure, consisting of 10 hours-a-day of 
sleeping at 14.8-14.3% O2 (simulating 2800–3000m altitude), 30 minute exercise bouts at 15.4% O2 
(simulating 2500m altitude) three times per week, and additional sea level training. They found that 
individuals with the lowest number of CAG repeat units (≤21) had a greater increase in V̇O2max 
following hypoxic training than those with a higher number of repeats (>21) (∆V̇O2max; ≤21 CAG repeats 
11.9% increase, >21 CAG repeats 3.6% increase; P=0.004).  
 
3.7 High altitude population ancestry 
Two papers from the same group measured a number of physiological variables, including V̇O2max, at 
altitude in Peruvian males of mixed Quechua and Spanish origins [13, 14]. Both sought to determine 
whether individuals with stronger Quechua (historical long-term high altitude resident) origins had 
favourable physiological responses to altitude. We considered excluding these two papers as, strictly 
speaking, they do not meet one of the inclusion criteria: to ‘seek to identify genetic factors.’ However, 
we did include them given that they studied exercise performance at altitude and separated individuals 
based on their genetic profile. The first, published in 2004, comprised two groups from Peru; a group 
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resident in Lima (sea level) and a group resident in Cerro de Pasco (4388m) [13]. No association was 
found between V̇O2max values at an altitude of 4388m, and the degree of Quechua, Spanish and African 
ancestry, as indicated by 22 genetic markers. The second study [14] has used the same lowland 
population and the same genetic profiling as the 2004 study [13] (confirmed with primary author of the 
manuscripts via email correspondence) and analysed the influence of genetic admixture on the 
magnitude of the V̇O2max decrement from sea level to high altitude (data not presented in the same 
author’s 2004 paper). After controlling for other covariates, genetic admixture explained a significant 
proportion of the variation (β = - 0.205) in the decrement in V̇O2max from sea level to high altitude (P = 
0.041), with those with a higher Quechua (and lower Spanish) genetic ancestry maintaining sea level 
V̇O2max values to a greater degree. 
 
3.8 Study quality 
As the method of assessing study quality is not validated and may only provide a guide to the quality of 
reporting of the research, we have not commented on each study individually. Instead we aim to 
identify trends in the available literature where the conduct and/or reporting of research could be 
improved. The median score achieved in the study quality analysis was 6 out of 10 for case control 
studies, 8 out of 10 for cohort studies with a discrete outcome, 6 out of 9 for cohort studies with a 
continuous outcome, and 4.5 out of 8 for genetic admixture studies (Table 6). The study quality score 
ranged considerably between studies, for example in cohort studies with a continuous outcome the 
total score ranged from 2-7 out of 9. 
 
In the case-control studies, the descriptions of the case groups were adequate with both the studies 
given a score of one [6, 15]. However, only one of the control groups was deemed adequate [15], with 
the other study failing to provide adequate information about whether the level of relatedness of 
participants was controlled [6]. The majority of studies in which testing for Hardy-Weinberg (HW) 
equilibrium was appropriate did so (7 of 8). The one study that did not test for HW equilibrium had very 
small subject numbers (n=8) and so it would have provided very little information [7]. In the other three 
studies, two investigated whether genetic admixture was associated with performance. This approach 
utilised polymorphisms that differed according to ancestry, meaning that testing for HW equilibrium 
would be uninformative [13, 14]. In the other study, the polymorphism was located on the X 
chromosome and the populations were male so genotype distribution would not conform with HW 
equilibrium, evidence of which was thus not sought [12]. 
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Three study quality criteria relate to genotyping methods and reporting: providing the sequence of 
primers, demonstrating the reproducibility of the genotyping methods, and adequately blinding the 
genotyping staff from the phenotype details. Most studies (7 of 11) provided the details of the primer 
sequence (or a reference to them), one stated that this would be made available on request [11], two 
gave reference to a website which could be used to identify them [13, 14], and one failed to provide any 
information [7]. Eight studies stated that they had validated their genotyping methods or cited a 
reference for a validation study, while only two studies stated that their genotyping staff were blinded 
from the phenotype data.  
The statistical merit of each paper was analysed in three of the study quality criteria. These analysed if 
appropriate statistical tests were performed, if adjustments were made to account for multiple 
comparisons in studies analysing more than one polymorphism, and if power calculations were made. 
Ten of the eleven studies used appropriate formal methods of comparison to establish if difference 
were present between groups. Only one study did not use a formal test of significance, and this was 
probably justified because the small number of participants would have precluded any meaningful 
results being obtained [7]. Only one study analysed several polymorphisms and failed to make 
adjustments for multiple comparisons [6]. Four of the eleven studies conducted sample size calculations 
[6, 8, 11, 13], with one study performing the calculation prior to conducting the study [11]. 
 
No article included in the review provided both a study identifying a potential polymorphism and a study 
validating the original finding. Following the original paper analysing the association between the ACE 
I/D polymorphism and mountaineering performance by Montgomery et al. [15], several other papers 
analysed the association between this polymorphism and highly related phenotypes [6, 8-10].  
Furthermore, one study replicated polymorphisms related to endurance performance at sea level using 
an endurance race at altitude as the phenotype [11].  
 
4 Discussion 
4.1 Main findings 
This review identified four genetic polymorphisms associated with hypoxic exercise performance: 
AMPD1 C34T, ADRB2 GA, androgen receptor CAG repeat, and the ACE I/D polymorphisms. Support for 
the association between the ACE I allele and high altitude performance was the strongest, with three 
studies identifying a positive relationship between the I allele and improved performance. Conversely, 
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the AMPD1 34T allele and the ADRB2 16Arg allele were associated better performance in atmospheric 
hypoxia in one study, while those with the lowest number of CAG repeat units in the androgen receptor 
had better V̇O2max gains following hypoxic training in one study. This review identified that the number 
of articles and the total number of polymorphisms studied within this area are few; only eleven articles 
were identified and only thirteen polymorphisms within 10 different genes studied. In addition, the 
conduct and/or reporting of the studies was not optimal with many failing to select and describe the 
populations adequately, several not conducting or describing their genotyping methods sufficiently and 
many conducted without calculating the correct sample size required to adequately power the study.  
 
4.2 Study number and design 
The small number of articles identified in the current review and the limited number of polymorphisms 
studied in total highlights that the influence of genetic factors on exercise performance in hypoxia has 
not been studied in depth.  This is in contrast to the hundreds of articles that have studied the influence 
of genetics on other phenotypes such as exercise performance at sea level [16]. The majority of studies 
have taken the candidate gene approach (n = 9), whilst two studied whether genetic admixture 
influenced exercise performance [13, 14]. The limited range of SNPs studied is likely due to a bias 
towards studying genes associated with exercise and/or altitude phenotypes in previous publications 
and to the reliance on the candidate gene approach. The absence of genome-wide association studies is 
notable as it would allow hypothesis-free investigation and help identify novel candidate genes for 
which the biological pathway is not known. This approach is commonplace in many other fields of 
research and has been used successfully to identify polymorphisms associated with V̇O2max gains at sea 
level [17], obesity [18] and blood pressure [19]. The candidate gene approach is justified as it has greater 
power to detect difference in genotype frequency between groups, and is suited to studies using 
modest population sizes [20]. Despite most studies using the candidate gene method, study designs 
differed greatly with regards to the population, hypoxic exposure, and the performance phenotype. The 
small number of studies, in addition to the variety of study designs, makes comparison between studies 
difficult, and limits the ability to assess the reliability of results. The variety of study designs, 
polymorphisms and outcomes studied, and the small number of studies precluded meaningful formal 
assessment of bias, such as a funnel plot [21]. That said, in spite of small samples sizes, seven of the nine 
candidate gene studies identified an association between a polymorphism and the performance 
phenotype with effect sizes considered very large for genetic association studies [22]. These factors may 
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point towards some form of bias within the literature base, although this cannot be confirmed at this 
time. 
 
4.3 Genetic polymorphisms associated with exercise performance during hypoxic exposure 
This review identified four polymorphisms associated with exercise performance in a hypoxic 
environment, and found nine polymorphisms to have no relationship (Tables 3, 4 and 5). Furthermore, 
in a study of Peruvian natives a genetic profile with a greater Quechua (as opposed to Spanish) origin 
was associated with greater preservation of V̇O2max at altitude [14].  
 
4.4 ACE insertion/deletion (I/D) polymorphism (rs4646994) 
The ACE I/D polymorphism had the most supporting literature with three studies observing an 
association of the I-allele (lower ACE activity) with mountaineering performance [9, 10, 15]. ACE is an 
important component of the endocrine renin-angiotensin system (RAS), converting angiotensin I to 
angiotensin II, which exerts pressor effects through arteriolar vasoconstriction and aldosterone-
mediated salt and water retention [23]. However, cellular and tissue RAS are now known to exist in 
multiple tissues [23] where they have diverse roles relating to the regulation of cell growth and survival, 
metabolism and inflammation [24]. The presence (insertion, I-allele) rather than absence (deletion, D-
allele) of a 287bp fragment in the ACE gene (rs4646994) is associated with lower circulating [25] and 
tissue [26, 27] ACE activity. Whilst the mechanism underpinning the association between the ACE I/D 
polymorphism and mountaineering performance has yet to be fully established, the I-allele has been 
associated with enhanced endurance performance at sea level [28], greater hypoxic ventilatory drive 
[29], enhanced arterial oxygenation at altitude [30], and enhanced training-related gains in metabolic 
efficiency [31].  
 
It should be noted that three studies found no association between the ACE ID polymorphism and their 
hypoxic exercise performance phenotype of interest [5, 7, 8] and one presented incorrect results [6]. 
The others found no ACE genotype association with V̇O2max at 4338m in Peruvian natives [5] or change 
in endurance running performance following hypoxic training [7]. This later study, however, had limited 
power to detect any difference in genotype distribution due a very small sample size.  These results are 
important in their own right, but it is entirely plausible that an association exists between the ACE 
polymorphism and mountaineering performance that is mediated by a mechanism unrelated to 
V̇O2max. The lack of association between the polymorphism and mountaineering performance in the 
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study by Kalson et al. [8] is more difficult to explain. However, despite the altitude exposure and 
performance phenotype being similar in all four studies there are still subtle differences in ascent rate, 
maximum altitude of exposure and total time at high altitude which may explain the discrepancy. 
Furthermore, Kalson et al.  [8] acknowledged that they had insufficient sample size to detect a 
difference between successful and unsuccessful climbers and were therefore at risk of a type 2 error. 
The lack of power due to small sample size is a limitation of many of the reviewed studies and will be 
discussed further in the Study quality section. 
 
4.5 ACTN3 R577X (rs1815739) 
The ACTN3 gene encodes the protein alpha actinin-3- an actin binding protein expressed predominantly 
in type II (fast) muscle fibres, which has structural, cell signalling and metabolic roles [32, 33]. The 
ACTN3 gene contains a nonsense polymorphism that results in the substitution of an arginine (R) with a 
stop codon (X) at amino acid 577 on the alpha actinin-3 protein (rs1815739) [34]. The premature 
termination of the alpha actinin-3 protein associated with homozygosity for the R577X null allele results 
in complete alpha actinin-3 deficiency, and occurs in approximately 16% of the world population [34]. 
Whilst this deficiency does not cause muscle disease, possibly due to compensation by the closely 
related isoform alpha actinin-2, it does appear to influence sporting performance [32]. The frequency of 
the ACTN3 alleles was reported to differ between a ‘normal’ population, an elite sprint and power 
athletic population, and an elite endurance athletic population (P<0.001), with elite power athletes 
having a lower frequency of the XX genotype (normal, 18%; elite power, 6%) and elite endurance 
athletes having a higher frequency of XX genotype (normal, 0.16; elite endurance, 0.24) [35].  The two 
studies identified in our review, do not support an association between the ACTN3 R577X polymorphism 
and exercise performance at high altitude [6, 11]. However, given the limited performance phenotypes 
investigated and the flawed statistical analysis in Djarova’s study [6] an association cannot be excluded. 
 
4.6 AMPD1 C34T (rs17602729) 
Adenosine monophosphate deaminase (AMPD) catalyses the conversion of adenosine monophosphate 
(AMP) to inosine monophosphate (IMP) and ammonia which, in turn, moves the myokinase equilibrium 
reaction (2 ADP ⇌ ATP + AMP) towards ATP resynthesis [36]. The AMPD1 gene contains a genetic 
variation (C34T) which results in the replacement of a glutamine amino acid with a stop codon and has 
an allele frequency of 13.7% in a healthy Caucasian population [37]. Norman et al. (1998) also showed 
that AMPD activity in skeletal muscle of AMPD1 TT homozygotes was <1% that of CC homozygotes, and 
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that heterozygotes had intermediate activity levels. At sea level the AMPD1 TT homozygotes have been 
shown to have ∼14% lower peak power output than their CT/CC counterparts (P<0.05) [38] and the 
frequency of the T allele is lower in elite endurance athletes compared to controls (0.043 Vs 0.085; 
P<0.05) [39].  Tsianos et al. [11] also found an association between the AMPD T allele and Mt Olympus 
Marathon performance in athletes whose preferred endurance sport was running. It is thus unclear if 
and whether AMPD1 genotype is associated with endurance performance per se or with hypoxic 
endurance performance.  No data are available to answer this question. The result must be viewed with 
some caution as they were obtained in a sub-population of the whole group studied and are yet to be 
verified in other high-altitude exercise phenotypes (we do not consider the results of Djarova et al. [6] 
valid).  
 
4.7 Other polymorphisms 
The adrenergic receptors are G protein coupled receptors which are expressed in a wide range of tissues 
and cause a variety of physiological responses in response to binding with circulating catecholamines 
[40]. The beta2-adrenergic receptor sub-group has a primary function to facilitate a sympathetic 
nervous system response, altering respiratory, cardiac and vascular function [41]. In a meta-analysis, the 
pooled frequency of the ADRB2 minor (16Arg) allele was 0.420 in Caucasians, 0.492 among populations 
with an African heritage (African-American, African, and Afro-Caribbean populations), and 0.562 among 
Oriental populations [42]. The ADRB2 polymorphism alters physiological function; compared to their 
ADRB2 Gly/Gly counterparts, 16Arg homozygotes have lower receptor density on isolated lymphocytes 
[43], lower resting stroke volume and cardiac output [44, 43], and lower sub maximal exercising stroke 
volume and mean arterial pressure [44]. Furthermore, the Arg/Arg genotype was more prevalent in an 
elite male endurance athlete population than in a control populations consisting of geographically 
matched males (0.17 Vs 0.09, P=0.03). 
 
This review identified one study in which the beta2-adrenergic receptor (ADRB2) Arg allele was 
associated with better endurance exercise performance at altitude. Tsianos et al. [11] found the Arg 
allele was associated better performance in the Mt Olympus Marathon amongst people whose 
preferred mode of exercise was running, and with best ever Mt Olympus Marathon time amongst those 
who had completed the event several times. As described in the previous section regarding similar 
results for the AMPD1 C34T SNP, these results should be viewed with caution given that these 
associations were established for particular sub-groups and were only sought and identified in one 
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study. However (and again as described above), the results are aligned with those at sea level which 
increases the confidence in the validity of such findings.  
 
Androgens, such as testosterone, act by binding to the AR, and their effects on anthropometric variables 
and physical performance (including increasing fat free mass, muscle strength and size) are well 
described [45]. In skeletal muscle cells, the AR CAG repeat polymorphism alters the receptor’s 
transcriptional activity, with higher repeat lengths causing greater activity, as well as altering markers of 
cell growth and development [46]. Wang et al. [12] identified an association between those with a lower 
number of CAG repeat units (≤21) and a greater increase in V̇O2max following hypoxic training. 
However, a normoxic control population was not employed and therefore the increases in V̇O2max, and 
the association with the AR polymorphism, may simply reflect a training effect.  Further studies designed 
to distinguish the effect of training from that of hypoxia are required. 
 
4.8 High altitude population ancestry 
The two related studies by Brutsaert and colleagues [13, 14] found no association between the degree 
of Quechua, Spanish and African ancestry in population of Peruvian males, as indicated by 22 genetic 
markers, and V̇O2max values at an altitude of 4,388 meters. They did however find that the magnitude 
of the decrease in V̇O2max from sea level to high altitude was lower in those with a greater degree of 
Quechua ancestry. The specific mechanisms to explain this exercise performance phenotype are not 
readily forthcoming as the data in this field are sparse; however, a genetically-mediated reduction in 
SaO2 during maximal exercise appears to have a role [14]. This finding adds to a growing body of 
literature suggesting that the Quechua have altered anthropological and physiological responses to 
hypoxia as a result of genetic selection [47].   
 
4.9 Study quality 
Analysis of study quality highlights a need for better conduct and/or reporting of genetic association 
studies in this field. The selection of populations, genotyping practices, and statistical procedures were 
inadequate in many of the studies (Table 6) and only three studies attempted to replicate prior findings 
using similar phenotypes [8-10]. Some studies did not ensure that ethnicity of populations was 
accounted for in the analysis process, country of origin often being an inadequate descriptor. Selecting 
unrelated populations of the same ethnicity is critical to avoid population stratification which can 
confound results and lead to spurious association being identified [48]. However, such problems are 
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hard to overcome in ‘field’ research. Poor genotyping practices may also lead to erroneous results and 
can be caused by many factors including; collecting low quality and/or quantity of DNA, machine error 
or failure, human error, poor storage conditions, and issue with the array [49]. Despite this, only eight 
studies stated that they had checked the validity of their genotyping procedure or cited a reference for a 
validation study [5, 9-12, 14, 15], and only two blinded genotyping staff from phenotypic data [8, 9]. 
Meanwhile seven studies provided sufficient primer information to allow replication. Seven of the 
eleven studies failed to conduct sample size calculations, and only one study performed the calculation 
prior to conducting the study. The majority of studies included in the review seem underpowered to test 
their hypothesis effectively as the associations between SNPs and complex human phenotypes, such as 
exercise performance, are generally small [22]. The studies in this review typically had a sample size 
under 100, whereas it has been suggested that to adequately power genetic association studies 
investigating complex multifactorial traits, studies should employ sample sizes well in excess of this 
number [22]. Finally, replication of initial findings is of paramount importance because a first study often 
overestimates the size of the effect when compared to subsequent studies, and in many cases the 
subsequent studies fail to support the initial findings [50]. The studies we reviewed failed to validate 
initial findings by testing the same genetic polymorphism on a similar population and phenotype. 
However the association between the ACE polymorphism and mountaineering performance identified 
by Montgomery et al. [15] was evaluated in similar populations in three subsequent studies, albeit using 
different study designs [8-10].   
 
4.10 Strengths and Limitations of the review 
The strengths of the review are that it used systematic search and analysis methodologies to identify 
studies that have investigated the association between genetic factors and exercise performance in 
atmospheric hypoxia.  This allowed us to identify all studies in the area and avoided selection bias.  
Identifying these polymorphisms will guide future research, identifying targets for further study and 
helping to avoid the repetition of work. The review also analysed the conduct and/or reporting of the 
studies giving an indication of study quality and highlighting where improvements in study design can be 
made.  
 
Limitations of this study include the method of study selection.  It may have been helpful to exclude 
studies based on study design and/or quality to provide a clearer picture of which polymorphisms and 
molecular systems are important in hypoxic exercise performance. However, the lack of a robust 
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validated method of analysing study design and quality in genetic association studies made this difficult.  
Consequently we adapted Clark and Baudouin’s [4] method of analysing study quality.  This method has 
not been validated and thus it is unclear whether it indicates greater study validity, or the likelihood of 
replication. However, it does follow previous studies and articles that give recommendations for how 
genetic association studies should be conducted and presented [51, 52].  
 
5 Conclusions 
This review shows that the association between genetic polymorphisms and high altitude exercise 
performance has not been studied in depth. We identified only eleven articles which studied a total of 
just thirteen genetic polymorphisms. Four polymorphisms were associated with hypoxic exercise 
performance: AMPD1 C34T, ADRB2 GA, androgen receptor CAG repeat, and the ACE I/D polymorphisms. 
The strongest association appears to be between the ACE I allele and enhanced high altitude 
mountaineering performance with three studies identifying a relationship. The study quality analysis 
highlighted deficiencies in the conduct and reporting of the genetic association studies. The selection 
and description of populations, genotyping methods, and statistical analysis procedures were 
inadequate in many of the studies. In particular, many studies failed to calculate the correct sample size 
required to adequately power their study and subsequently most appear underpowered to test their 
hypothesis effectively. To attain greater understanding of the role that genetic factors have on high 
attitude exercise performance, further studies need to be performed. Future studies should endeavour 
to use more robust study design (e.g. appropriate sample size, replicable phenotypes, robust methods of 
selecting study and control populations) and ensure they provide adequate information to permit 
subsequent replication or meta-analysis. Furthermore, genome wide studies should be considered in 
future in order to help identify novel biological pathways of hypoxic adaptation.  
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Table 1. Study quality scoring assessment system 
Item Criterion Score 
1.  Control group Was the control/comparison group equal or larger in size than the 
case group, and was; 
 it described in such a way that it could be replicated 
 it stated or inferred that the ethnicity of the control group 
was not different to that of the case group.  
If the control group from a previous study was used and 
referenced, the referenced study was retrieved and the control 
group analysed as above. No score was assigned to cohort studies 
for this item. 
Yes = 1 
No = 0 
2. Hardy-Weinberg 
equilibrium 
Were the groups included in the study assessed for to determine if 
they were in Hardy-Weinberg equilibrium? 
Yes = 1 
No = 0 
3. Case group/whole 
group 
Is the definition of the case group adequate to allow replication? 
For cohort studies, is the description of the whole group sufficient 
for replication? 
Yes = 1 
No = 0 
4. Primer Were the primer sequences provided or was a reference to these 
given? 
Yes = 1 
No = 0 
5. Reproducibility of 
genotyping 
Was the description of genotyping methods sufficient to allow 
replication or was a reference providing this information given?  
and was the validity of the genotyping technique checked by 
performing a second assay technique, by validating the accuracy 
the assay used, or was a reference to a validation study given?  
 
Yes = 1 
No = 0 
6. Blinding Were genotyping staff blinded from group allocation or phenotypic 
data? 
Yes = 1 
No = 0 
7. Power calculation Was a power calculation performed either prospectively or 
retrospectively? 
Yes = 1 
No = 0 
8. Statistics Were major findings presented with well described tests of 
significance including p values, odds ratios or confidence intervals? 
Yes = 1 
No = 0 
9. Corrected statistics When more than one genetic polymorphism was studied, were 
statistical corrections made to account for the increased risk of a 
false positive? a One-tailed significance testing was also scored as 
zero. Those testing one genetic polymorphism were scored as one. 
Yes = 1 
No = 0 
10. Independent Was a secondary confirmatory study performed, or does the study Yes = 1 
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replication specifically state it is being performed to confirm results from an 
earlier study? 
No = 0 
aif the study only investigated one genetic polymorphisms the question was scored as ‘1’. 
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Table 2. Exercise performance in atmospheric hypoxia and candidate genes; case-control studies 
  Case   Control    
Gene Polymorphism N (number of 
males) 
Population Frequency  N (number of 
males) 
Population Frequency P 
Value 
Odds ratio Reference 
ACE I/D  
(rs4646994) 
25 (25 males) Elite British mountaineers  
 
II: 12 (0.48) 
ID: 11 (0.44) 
DD: 2  (0.08) 
 1906 (1906 
males) 
British – free 
from CV disease 
 
II: (0.26) 
ID: (0.50) 
DD:  (0.24)a 
0.02 2.43 
 
Montgomery 
et al. (1998) 
[15] 
  
 
5 (not stated) Bulgarian elite high-altitude 
mountaineers 
II: 1 (0.20) 
ID: 4 (0.80) 
DD: 0 (0.00) 
 72 (not stated) Athletic Bulgarian 
students 
II: 8 (0.11) 
ID: 41 (0.57) 
DD: 23 (0.32) 
0.024
~ 
2.29 Djarova et al. 
(2013) [6] 
ACTN3 
 
R577X 
(rs1815739) 
5 (not stated) Bulgarian elite high-altitude 
mountaineers 
RR: 1 (0.20) 
RX: 3 (0.60) 
XX:1 (0.20) 
 72 (not stated) Athletic Bulgarian 
students 
RR: 30 (0.42) 
RX: 32 (0.44) 
XX: 10 (0.14) 
0.032
bc 
1.77 Djarova et al. 
(2013) [6] 
AMPD1 
 
G/A 
(rs17602729) 
5 (not stated) Bulgarian elite high-altitude 
mountaineers 
CC: 3 (0.60) 
CT: 1 (0.20) 
TT: 1 (0.20) 
 72 (not stated) Athletic Bulgarian 
students 
CC: 53 (0.74) 
CT: 19 (0.26) 
TT: 0 (0.00) 
0.003
bc 
2.82 Djarova et al. 
(2013) [6] 
avalues taken from subsequent paper using the same population; bStatistic for allele comparisons; cstatistical analysis appears to be incorrect; CV, cardiovascular. 
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Table 3. Exercise performance in atmospheric hypoxia and candidate genes; cohort studies separated by summit success. 
  Task success  Task failure    
Gene Polymorphism N (number of 
males) 
Population Frequency  N (number of 
males) 
Population Frequency P 
Value 
Odds 
ratio 
Referen
ce 
ACE I/D  
(rs4646994) 
183 (not stated – 
whole 
population: 83% 
male) 
Caucasians successful in 
summiting Mt Blanc 
(4,807 m) 
II: 40 (0.22) 
ID: 93 (0.51) 
DD: 50 (0.27) 
 12 (not stated) Caucasians who failed 
to summit Mt Blanc 
(4,807 m) 
II: 0 (0.00)  
ID: 5 (0.42)  
DD: 7 (0.58) 
0.048 3.41 Tsianos 
et al. 
(2005) 
[10] 
  92 (not stated – 
whole 
population: 90% 
male) 
Caucasians and Asian 
mountaineers  Successful 
in summiting > 8,000 m 
II: 30 (0.33)  
ID: 41 (0.45) 
DD: 21 (0.23) 
 57 (not stated) Caucasians and Asian 
mountaineers  
unsuccessful in 
summiting > 8,000 m 
II: 3 (0.06)  
ID: 28 (0.60) 
DD: 16 (0.34) 
0.003 2.15 Thomps
on et 
al. 
(2007) 
[9] 
  41 (not stated – 
whole 
population: 60% 
male) 
Successfully ascended to 
5,895 m with a slow 
ascent profile 
II: 9 (0.22) 
ID: 18 (0.44) 
DD: 14 (0.34)  
 41 (not stated) Unsuccessful in an 
attempt to 5,895 m 
with a slow  ascent 
profile 
II: 9 (0.22) 
ID: 22 (0.54) 
DD: 10 (0.24) 
0.54 0.82 Kalson 
et al. 
(2009) 
[8] 
  20 (not stated – 
whole 
population: 60% 
male) 
Successfully ascended to 
5,895 m with a fast 
ascent profile 
II: 6 (0.30) 
ID: 11 (0.55) 
DD: 3 (0.15) 
 14 (not stated) Unsuccessful in an 
attempt to 5,895 m 
with a fast ascent 
profile 
II: 0 (0.00) 
ID: 10 (0.71) 
DD: 4 (0.29) 
0.09 2.44 Kalson 
et al. 
(2009) 
[8] 
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Table 4. Exercise performance in atmospheric hypoxia and candidate genes; cohort studies studying a continuous trait. 
Gene Polymorphism 
(rs number) 
Number of 
participants 
(male/female) 
Phenotype 
 
Genotype frequency Results (performance separated by 
genotype) 
P 
value 
Reference 
ACE I/D  
(rs4646994) 
7 competitive runners Sea level time 
trial performance 
change following 
hypoxic training 
II: 0 (0.00) 
ID: 3 (0.38) 
DD: 5 (0.62) 
Sea level time trial performance 
change organised by genotype was 
not given 
Not 
given 
- NS 
Hinckson et 
al. (2005) [7] 
ACE I/D  
(rs4646994) 
142 Peruvians  
68 lowlanders (32 
male)  
74 highlanders (39 
male) 
V̇O2max at high 
altitude (4438 m) 
Lowlanders: 
II: 36 (0.53) 
ID: 23 (0.34) 
DD: 9 (0.13) 
 
Highlanders: 
II: 38 (0.51) 
ID: 31 (0.42) 
DD: 5 (0.07) 
V̇O2max (ml/kg/min) - mean (SE); 
II: 35.3 (0.6) 
ID: 34.9 (0.8) 
DD: 36.0 (1.5) 
0.663 Bigham et al. 
(2008) [5] 
AR Androgen 
receptor CAG 
repeat 
polymorphism 
65 Han Chinese 
athletes 
V̇O2max after 
hypoxic training 
(simulating 2800–
3000 m altitude) 
≤21 CAG repeats: 21 (0.32) 
>21 CAG repeats: 44 (0.68) 
V̇O2max (% change following 
training) - mean (SE); 
≤21 CAG repeats: 11.9% 
>21 CAG repeats: 3.6% 
0.004 Wang et al. 
2010 [12] 
ACTN3 
 
R577X 
(rs1815739) 
438 Greek athletes 
(417 males) 
Mt Olympus 
Marathon 
performance 
Not given Phenotype results were not given. 
No difference between 
genotypes/alleles 
0.20ab Tsianos et al. 
(2010) [11] 
AMPD1 
 
G/A 
(rs17602729) 
438 Greek athletes 
(417 males) 
Mt Olympus 
Marathon 
performance 
Not given Phenotype results were not given. 
No difference between 
genotypes/alleles 
0.34ab Tsianos et al. 
(2010) [11] 
BDKRB2 
 
C/T 
(rs1799722) 
438 Greek athletes 
(417 males) 
Mt Olympus 
Marathon 
Not given Phenotype results were not given. 
No difference between 
0.17a Tsianos et al. 
(2010) [11] 
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performance genotypes/alleles 
ADRB2 G/A 
(rs1042713) 
438 Greek athletes 
(417 males) 
Mt Olympus 
Marathon 
performance 
Not given Phenotype results were not given. 
No difference between 
genotypes/alleles 
0.21a Tsianos et al. 
(2010) [11] 
PPARGC1A A/G 
(rs8192678) 
438 Greek athletes 
(417 males) 
Mt Olympus 
Marathon 
performance 
Not given Phenotype results were not given. 
No difference between 
genotypes/alleles 
0.71a Tsianos et al. 
(2010) [11] 
PPARA 
 
G/C 
(rs4253778) 
438 Greek athletes 
(417 males) 
Mt Olympus 
Marathon 
performance 
Not given Phenotype results were not given. 
No difference between 
genotypes/alleles 
0.25a Tsianos et al. 
(2010) [11] 
PPARD 
 
T/C (rs6902123) 438 Greek athletes 
(417 males) 
Mt Olympus 
Marathon 
performance 
Not given Phenotype results were not given. 
No difference between 
genotypes/alleles 
0.24a Tsianos et al. 
(2010) [11] 
 T/C 
(rs1053049) 
438 Greek athletes 
(417 males) 
Mt Olympus 
Marathon 
performance 
Not given Phenotype results were not given. 
No difference between 
genotypes/alleles 
0.20a Tsianos et al. 
(2010) [11] 
 A/G 
(rs2267668) 
438 Greek athletes 
(417 males) 
Mt Olympus 
Marathon 
performance 
Not given Phenotype results were not given. 
No difference between 
genotypes/alleles 
0.71a Tsianos et al. 
(2010) [11] 
APOE E4 (rs7412)  438 Greek athletes 
(417 males) 
Mt Olympus 
Marathon 
performance 
Not given Phenotype results were not given. 
No difference between 
genotypes/alleles 
0.12a Tsianos et al. 
(2010) [11] 
 (rs429358) 438 Greek athletes 
(417 males) 
Mt Olympus 
Marathon 
performance 
Not given Phenotype results were not given. 
No difference between 
genotypes/alleles 
>0.05
a 
Tsianos et al. 
(2010) [11] 
aprobability value only for male athlete as values not given for the whole group; bsignificant differences were found between genotypes for other sub-group analysis; 
V̇O2max, maximum oxygen consumption; NS, not significantly different; SE, standard error. 
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Table 5. Symbols, names, and chromosomal location of all genes identified 
Gene Name Location 
ACE Angiotensin 1-converting enzyme 9q34.1-34.2 
ACTN3 Actinin, alpha 3 11q13-q14 
ADRB2 Adrenergic, beta 2, receptor  5q31-q32 
AMPD1 Adenosine monophosphate deaminase 1 1p13 
APOE Apolipoprotein E 19q13.2 
AR Androgen receptor Xq11-12 
BDKRB2 Bradykinin receptor B2 14q32.1-q32.2 
PPARA Peroxisome proliferative activated receptor, alpha 22q13.31 
PPARD Peroxisome proliferative activated receptor, delta 6p21.2-p21.1 
PPARGC1A Peroxisome proliferative activated receptor, gamma, 
coactivator 1, alpha 
4p15.1 
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Table 6. Study quality results 
Study ID Control 
group 
Hardy-Weinberg 
equilibrium 
Case group/ 
whole group 
Primer Reproducibility of 
genotyping 
Blinding Power 
calculation 
Statistics Corrected 
statistics 
Independent 
replication 
Total 
Case-control            
Montgomery 
et al. (1998) 
[15] 
1 1 1 1 1 0 0 1 1 0 7/10 
Djarova et al. 
(2013) [6] 
0 1 1 1 0 0 1 1 0 0 5/10 
Cohort: discrete outcome           
Tsianos et al. 
(2005) [10] 
0 1 1 1 1 0 0 1 1 1 7/10 
Thompson et 
al. (2007) [9] 
0 1 1 1 1 1 0 1 1 1 8/10 
Karson et al. 
(2009) [8] 
0 1 1 1 0 1 1 1 1 1 8/10 
Cohort: continuous 
outcome 
          
Hinckson et 
al. (2005) [7] 
- 0 1 0 0 0 0 0 1 0 2/9 
Bigham et al. 
(2008) [5] 
- 1 1 1 1 0 0 1 1 0 6/9 
Tsianos et al. 
(2010) [11] 
- 1 1 0 1 0 1 1 1 1 7/9 
Wang et al. 
(2009) [12] 
- 1a 1 1 1 0 0 1 1 0 6/9 
Genetic admixture           
Brutsaert et 
al. (2003)[14] 
- - 1 0 1 0 0 1 1 0 4/8 
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Brutsaert et 
al. (2004) [13] 
- - 1 0 1 0 1 1 1 0 5/8 
aPolymorphism located on the X chromosome and the populations were male so genotype distribution would not conform with Hardy-Weinburg equilibrium, this section was scored as 1. 
 
